

SEMINAIRE 2025

25 Novembre 14h30

Biserte

Meeting Room

Invitée par l'équipe « Lille Neurodegeneration »

Dr. Flavie Strappazzon

(Institut NeuroMyoGène, Lyon)

Targeting Tau Pathology through the Autophagic Receptor NDP52

Pathological Tau accumulation is a hallmark of Alzheimer's disease (AD) and a major driver of neurodegeneration. Early elimination of pathological Tau represents a promising therapeutic strategy. Hyperphosphorylated Tau can be degraded via selective autophagy, mediated by the receptor NDP52/CALCOCO2. We identified a natural variant, NDP52GE (rs550510), which promotes autophagy more efficiently than the wild-type protein. Our recent work shows that NDP52GE enhances clearance of pathological Tau and may act as a resilience factor in AD, highlighting autophagy enhancement via NDP52GE as a potential novel therapeutic approach.





